{"id":2993,"date":"2019-07-19T00:00:00","date_gmt":"2021-03-18T06:09:19","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=2993"},"modified":"2021-03-18T14:09:19","modified_gmt":"2021-03-18T06:09:19","slug":"latest-trends-of-treatment-for-alzheimers-disease-in-sessions-and-symposium-at-alzheimers-association-international-conference-aaic-2019","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2019\/07\/19\/latest-trends-of-treatment-for-alzheimers-disease-in-sessions-and-symposium-at-alzheimers-association-international-conference-aaic-2019\/","title":{"rendered":"LATEST TRENDS OF TREATMENT FOR ALZHEIMER\u2019S DISEASE IN SESSIONS AND SYMPOSIUM AT ALZHEIMER\u2019S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019"},"content":{"rendered":"

Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced the presentation and discussion\u00a0 about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat* research data on Alzheimer\u2019s disease (AD), were given in the AAIC\u2019s Focused Topic Session “Discussion of BACEi Trial Findings: Challenges and Opportunities” at the Alzheimer\u2019s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019. In addition, Eisai held a symposium focused on the rationale and opportunities for drug development for pre-clinical AD.<\/p>\n

 <\/p>\n

1. AAIC\u2019s Focused Topic Session (Discussion of BACEi Trial Findings: Challenges and Opportunities)<\/b><\/p>\n

In this session, each company presented information about their own BACE inhibitors. Eisai gave a comprehensive presentation about the findings from the following nonclinical and clinical studies, as well as the clinical study status in regard to elenbecestat.<\/p>\n